Clinical Trials Logo

Digestive System Diseases clinical trials

View clinical trials related to Digestive System Diseases.

Filter by:

NCT ID: NCT03543540 Completed - Celiac Disease Clinical Trials

Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease

Start date: May 1, 2018
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled clinical study in non-homozygous human leukocyte antigen (HLA)-DQ.2.5+ adults with celiac disease (CeD).

NCT ID: NCT03535727 Completed - Neoplasms Clinical Trials

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Start date: June 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.

NCT ID: NCT03518294 Completed - Liver Diseases Clinical Trials

NASH Fitness Intervention in Thrombosis Trial (NASHFit)

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival. The current standard of care for NAFLD is lifestyle changes through diet and exercise. The human genome and regulation of gene expression is influenced by physical activity. NAFLD is a prothrombotic state with derangements in all three phases of hemostasis leading to clinically important clotting events. Exercise can improve coagulation in healthy persons. In this proposal, we seek to begin a line of work to answer the question "Can lifestyle changes effectively mitigate the increased risk of clotting in patients with NAFLD?" focusing initially on the at-risk population genetically susceptible to advanced disease.

NCT ID: NCT03509220 Completed - Clinical trials for Gastrointestinal Disease

Safety and Efficacy of PBK-1701TC for Bowel Cleansing Before Colonoscopy

Start date: April 11, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy, safety and tolerability of PBK-1701TC for bowel cleansing before colonoscopy. Half the participants will receive PBK-1701TC and while the other will receive standard oral preparation.

NCT ID: NCT03503162 Completed - Colorectal Cancer Clinical Trials

Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System

Start date: May 17, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the potential improvement in colonoscopy procedure's outcomes when using the Pure-Vu System in hospitalized patients who are indicated for colonoscopy procedure.

NCT ID: NCT03482830 Completed - Stress Clinical Trials

Perioperative Metabolic and Hormonal Aspects in Major Emergency Surgery

PHASE
Start date: March 5, 2018
Phase:
Study type: Observational

Emergency laparotomies, which most often is performed due to high risk disease (bowel obstruction, ischemia, perforation, etc.), make up 11 % of surgical procedures in emergency surgical departments, however, give rise to 80 % of all postoperative complications. The 30-day mortality rates in relation to these emergent procedures have been reported between 14-30 %, with even higher numbers for frail and older patients. The specific reasons for these outcomes are not yet known, however, a combination of preexisting comorbidities, acute illness, sepsis, and the surgical stress response that arise during- and after the surgical procedure due to the activation of the immunological and humoral system, is most likely to blame. The complex endocrinological response and consequences of this response to emergency surgery are sparsely reported in the literature. The aim of this PHASE project is to evaluate and describe the temporal endocrine, endothelial and immunological changes after major emergency abdominal surgery, and to associate these changes with clinical postoperative outcomes.

NCT ID: NCT03475550 Completed - Clinical trials for Functional Gastrointestinal Disorders

Managing Side Effects in Clinical Practice

Start date: May 22, 2017
Phase: N/A
Study type: Interventional

This is a quality improvement health services study in the Division of Gastroenterology at Beth Israel Deaconess Medical Center (BIDMC).

NCT ID: NCT03455595 Completed - Clinical trials for Digestive System Disease

CONECCT (Colorectal Neoplasia Endoscopic Classification To Chose the Endoscopic Treatment)

Start date: February 1, 2017
Phase: N/A
Study type: Observational

Prospective study so as to evaluate CONECCT score to determine both histological tissue and therapeutic choice

NCT ID: NCT03440047 Completed - Clinical trials for Gastro-Intestinal Disorder

Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim

Start date: August 28, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to see if advanced endoscopic imaging may be helpful to accurately distinguish pathological tissue from normal tissue and guide therapy of endoscopically identified pathology.

NCT ID: NCT03383029 Completed - Clinical trials for Gastrointestinal Disorders

iEAT 2.0 Open Trial

Start date: November 29, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about the eating behaviors of children with chronic food refusal. Specifically, investigator's aim to see how the integrated Eating Aversion Treatment (iEAT) may affect a child's food consumption. The manual is a structured multidisciplinary treatment, including a psychologist and dietitian with consultation from a speech-language pathologist. The treatment is designed to increase the volume of foods a child eats and decrease their reliance on a feeding tube or formula. The manual includes informational handouts, data collection forms, and instructions to guide the increase in feeding demands while reducing reliance on formula to meet a child's nutritional needs. Children with chronic food refusal will participate in this study at the Marcus Autism Center. All children who enroll will receive the iEAT treatment. This involves 10 bi-weekly sessions that last approximately one hour, over the course of 5 months and a 1 month follow-up visit. Therefore, the study will last a total of 6 months.